Patient-reported outcomes and PRO remission rates in 12,262 biologic-naïve patients with psoriatic arthritis treated with TNF-inhibitors in routine care

Lykke Midtbøll Ørnbjerg*, Kathrine Rugbjerg, Stylianos Georgiadis, Simon Horskjær Rasmussen, Lennart Jacobsson, Anne Gitte Loft, Florenzo Iannone, Karen Minde Fagerli, Jiri Vencovsky, Maria José Santos, Burkhard Möller, Manuel Pombo-Suarez, Ziga Rotar, Bjorn Gudbjornsson, Ayse Cefle, Kari Eklund, Catalin Codreanu, Gareth Jones, Marleen van der Sande, Johan Karlsson WallmanMarco Sebastiani, Brigitte Michelsen, Jakub Závada, Michael John Nissen, Carlos Sanchez-Piedra, Matija Tomšič, Thorvardur Jon Love, Heikki Relas, Corina Mogosan, Merete Lund Hetland, Mikkel Østergaard

*Corresponding author af dette arbejde

Abstract

OBJECTIVE: To evaluate patient-reported outcomes (PROs) after initiation of tumor necrosis factor inhibitor (TNFi) treatment in European real-world patients with psoriatic arthritis (PsA). Further, to investigate PRO remission rates across treatment courses, registries, disease duration, sex and age at disease onset.

METHODS: Visual-analogue-scale or Numerical Rating Scale scores for pain, fatigue, patient global, and Health Assessment Questionnaire disability index (HAQ) from 12,262 PsA patients initiating a TNFi in 13 registries were pooled. PRO remission rates (pain ≤1, fatigue ≤2, patient global ≤2, HAQ ≤0.5) were calculated for patients still on drug.

RESULTS: For the 1st TNFi, median pain score was reduced by ≈50% (baseline/6/12/24 months: 6/3/3/2) as were fatigue (6/4/4/3), patient global (6/3/3/2) and HAQ scores (0.9/0.5/0.5/0.4). Six months' LUNDEX-adjusted remission rates for pain/fatigue/patient global/HAQ were 24%/31%/36%/43% (1st TNFi), 14%/19%/23%/29% (2nd TNFi) and (9%/14%/17%/20% (3rd TNFi). For bio-naïve patients with disease duration <5 years, 6-months LUNDEX-adjusted remission rates for pain/fatigue/patient global/HAQ were 22%/28%/33%/42%. Corresponding rates for patients with disease duration >10 years were 27%/32%/41%/43%. Remission rates were 33%/40%/45%/56% for men and 17%/23%/24%/32% for women. For patients <45 years at diagnosis, 6-months LUNDEX-adjusted remission rate for pain was 28% vs. 18% for patients ≥45 years.

CONCLUSION: In 12,262 biologic-naïve PsA patients, 6 months treatment with TNFi reduced pain by approximately 50%. Marked differences in PRO remission rates across treatment courses, registries, disease duration, sex and age at onset of disease were observed, emphasizing the potential influence of other factors than disease activity on PROs.

OriginalsprogEngelsk
TidsskriftJournal of Rheumatology
ISSN0315-162X
DOI
StatusE-pub ahead of print - 15 jan. 2024

Fingeraftryk

Dyk ned i forskningsemnerne om 'Patient-reported outcomes and PRO remission rates in 12,262 biologic-naïve patients with psoriatic arthritis treated with TNF-inhibitors in routine care'. Sammen danner de et unikt fingeraftryk.

Citationsformater